drugset / Trial / NCT00699582

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582 ↗

Phase 3 Completed 389 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.

Timeline

Start
2008-05
Primary completion
2010-12
Completion
2011-01

Outcome

Met primary endpoint

paper with significant reductions compared with placebo for both 8 mg (p < 0.001) and 12 mg (p = 0.011). PMID 22905857 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 8 mg —
Subject Perampanel Small molecule 12 mg —

Indications